Cargando…
Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?
Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938544/ https://www.ncbi.nlm.nih.gov/pubmed/33678195 http://dx.doi.org/10.1186/s40545-021-00298-8 |
_version_ | 1783661613012746240 |
---|---|
author | Zulzaga, Zuzaan Myagmarsuren, Erdenetuya Woerdenbag, Herman J. van Puijenbroek, Eugene P. |
author_facet | Zulzaga, Zuzaan Myagmarsuren, Erdenetuya Woerdenbag, Herman J. van Puijenbroek, Eugene P. |
author_sort | Zulzaga, Zuzaan |
collection | PubMed |
description | Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and international safety data. In Mongolia, adverse drug reaction (ADR) reporting activities have been implemented in the past decade. During this period, the basic structure and legal basis of an adverse drug reaction monitoring system was established. Because of the fragmented but growing healthcare system and the complexity of pharmaceutical issues in Mongolia, a sustainable process for the development of the adverse drug reaction reporting system is a key issue. The aim of this article is to disclose the Mongolian situation for the rest of the world and to share experiences on how an ADR reporting system can be developed towards a higher and more advanced level to contribute to both national and international drug safety issues. In this article, we review the features of the Mongolian health care and pharmaceutical systems, as well as the current development of the adverse drug reaction reporting system. |
format | Online Article Text |
id | pubmed-7938544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79385442021-03-09 Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? Zulzaga, Zuzaan Myagmarsuren, Erdenetuya Woerdenbag, Herman J. van Puijenbroek, Eugene P. J Pharm Policy Pract Commentary Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and international safety data. In Mongolia, adverse drug reaction (ADR) reporting activities have been implemented in the past decade. During this period, the basic structure and legal basis of an adverse drug reaction monitoring system was established. Because of the fragmented but growing healthcare system and the complexity of pharmaceutical issues in Mongolia, a sustainable process for the development of the adverse drug reaction reporting system is a key issue. The aim of this article is to disclose the Mongolian situation for the rest of the world and to share experiences on how an ADR reporting system can be developed towards a higher and more advanced level to contribute to both national and international drug safety issues. In this article, we review the features of the Mongolian health care and pharmaceutical systems, as well as the current development of the adverse drug reaction reporting system. BioMed Central 2021-03-08 /pmc/articles/PMC7938544/ /pubmed/33678195 http://dx.doi.org/10.1186/s40545-021-00298-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Zulzaga, Zuzaan Myagmarsuren, Erdenetuya Woerdenbag, Herman J. van Puijenbroek, Eugene P. Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? |
title | Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? |
title_full | Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? |
title_fullStr | Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? |
title_full_unstemmed | Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? |
title_short | Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? |
title_sort | legislation and current developments in adverse drug reaction reporting in mongolia: how far are we? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938544/ https://www.ncbi.nlm.nih.gov/pubmed/33678195 http://dx.doi.org/10.1186/s40545-021-00298-8 |
work_keys_str_mv | AT zulzagazuzaan legislationandcurrentdevelopmentsinadversedrugreactionreportinginmongoliahowfararewe AT myagmarsurenerdenetuya legislationandcurrentdevelopmentsinadversedrugreactionreportinginmongoliahowfararewe AT woerdenbaghermanj legislationandcurrentdevelopmentsinadversedrugreactionreportinginmongoliahowfararewe AT vanpuijenbroekeugenep legislationandcurrentdevelopmentsinadversedrugreactionreportinginmongoliahowfararewe |